The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“Some in vitro studies suggest that PD-L1 and PD-L2 can inhibit T cell proliferation and cytokine productio”
BackgroundSelf-citationRestoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Self-citationPD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Self-citationDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Self-citationCTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Effector and memory T-cell differentiation: implications for vaccine development
Kaech, S. M., Wherry, E. J., & Ahmed, R. (2002) · Nature Reviews Immunology · doi:10.1038/nri778 · Cited by 1,865
Self-citation
Cited by
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Self-citationIFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
“Kenilworth, New Jersey, USA: Merck Sharp & Dohme Corp.; 2017.”
InfluentialThe PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
Self-citationPD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
“While the latter occurs focally at sites of IFNg-mediated immunologic attack, oncogene-driven PD-L1 expression is constitutive and diffuse (13).”
BackgroundPD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
Self-citationBlackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Self-citationCD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 1,975
Self-citationAhmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach
Hotchkiss, R. S., Monneret, G., & Payen, D. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70001-x · Cited by 1,442
Pitt, J. M., Marabelle, A., Eggermont, A., Soria, J.-C., Kroemer, G., & Zitvogel, L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw168 · Cited by 1,338
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,231
Self-citationNeutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,079
Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways
Fife, B. T., & Bluestone, J. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00662.x · Cited by 1,054
Redefining Chronic Viral Infection
Virgin, H. W., Wherry, E. J., & Ahmed, R. (2009) · Cell · doi:10.1016/j.cell.2009.06.036 · Cited by 1,031
Self-citationDendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
Jin, H.-T., Anderson, A. C., Tan, W. G., West, E. E., Ha, S.-J., Araki, K., Freeman, G. J., Kuchroo, V. K., & Ahmed, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009731107 · Cited by 858
“However, blockade of PD-1 pathway does not completely restore T-cell function (4, 5, 7), indicating the involvement of other negative regulatory pathways in CD8 T-cell exhaustion.”
BackgroundSelf-citationGao, Q., Wang, X.-Y., Qiu, S.-J., Yamato, I., Sho, M., Nakajima, Y., Zhou, J., Li, B.-Z., Shi, Y.-H., Xiao, Y.-S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1608 · Cited by 813
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778
Sharma, M. D., Baban, B., Chandler, P., Hou, D.-Y., Singh, N., Yagita, H., Azuma, M., Blazar, B. R., Mellor, A. L., & Munn, D. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31911 · Cited by 792
PD-L1 expression in human cancers and its association with clinical outcomes
Yu, J., Wang, X., Teng, F., & Kong, L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105862 · Cited by 787
Deciphering the transcriptional network of the dendritic cell lineage
the Immunological Genome Consortium, Miller, J. C., Brown, B. D., Shay, T., Gautier, E. L., Jojic, V., Cohain, A., Pandey, G., Leboeuf, M., Elpek, K. G., et al. (2012) · Nature Immunology · doi:10.1038/ni.2370 · Cited by 781
Enhancing SIV-specific immunity in vivo by PD-1 blockade
Velu, V., Titanji, K., Zhu, B., Husain, S., Pladevega, A., Lai, L., Vanderford, T. H., Chennareddi, L., Silvestri, G., Freeman, G. J., et al. (2009) · Nature · doi:10.1038/nature07662 · Cited by 771
Self-citationRegulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen, J., Jiang, C. C., Jin, L., & Zhang, X. D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv615 · Cited by 767
Good-Jacobson, K. L., Szumilas, C. G., Chen, L., Sharpe, A. H., Tomayko, M. M., & Shlomchik, M. J. (2010) · Nature Immunology · doi:10.1038/ni.1877 · Cited by 691
Self-citationvan de Veen, W., Stanic, B., Yaman, G., Wawrzyniak, M., Söllner, S., Akdis, D. G., Rückert, B., Akdis, C. A., & Akdis, M. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.01.014 · Cited by 652
Casey, K. A., Fraser, K. A., Schenkel, J. M., Moran, A., Abt, M. C., Beura, L. K., Lucas, P. J., Artis, D., Wherry, E. J., Hogquist, K., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200402 · Cited by 639
Self-citationBadoual, C., Hans, S., Merillon, N., Van Ryswick, C., Ravel, P., Benhamouda, N., Levionnois, E., Nizard, M., Si-Mohamed, A., Besnier, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2606 · Cited by 633
Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 607
Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade
Blackburn, S. D., Shin, H., Freeman, G. J., & Wherry, E. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801497105 · Cited by 579
Self-citationThe Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Mahoney, K. M., Freeman, G. J., & McDermott, D. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.018 · Cited by 571
Self-citationBallesteros-Tato, A., León, B., Graf, B. A., Moquin, A., Adams, P. S., Lund, F. E., & Randall, T. D. (2012) · Immunity · doi:10.1016/j.immuni.2012.02.012 · Cited by 542
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
Kinter, A. L., Godbout, E. J., McNally, J. P., Sereti, I., Roby, G. A., O’Shea, M. A., & Fauci, A. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6738 · Cited by 513
Strioga, M., Pasukoniene, V., & Characiejus, D. (2011) · Immunology · doi:10.1111/j.1365-2567.2011.03470.x · Cited by 505
PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
Dermani, F. K., Samadi, P., Rahmani, G., Kohlan, A. K., & Najafi, R. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27172 · Cited by 504
Yamaguchi, H., Hsu, J.-M., Yang, W.-H., & Hung, M.-C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00601-9 · Cited by 493
CD8+ T Cell Exhaustion in Cancer
Dolina, J. S., Van Braeckel-Budimir, N., Thomas, G. D., & Salek-Ardakani, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.715234 · Cited by 489
Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?
Akbar, A. N., & Henson, S. M. (2011) · Nature Reviews Immunology · doi:10.1038/nri2959 · Cited by 474
PD-L1 Expression in Lung Cancer
Yu, H., Boyle, T. A., Zhou, C., Rimm, D. L., & Hirsch, F. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.014 · Cited by 482
Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection
Butler, N. S., Moebius, J., Pewe, L. L., Traore, B., Doumbo, O. K., Tygrett, L. T., Waldschmidt, T. J., Crompton, P. D., & Harty, J. T. (2012) · Nature Immunology · doi:10.1038/ni.2180 · Cited by 482
Shin, H., Blackburn, S. D., Intlekofer, A. M., Kao, C., Angelosanto, J. M., Reiner, S. L., & Wherry, E. J. (2009) · Immunity · doi:10.1016/j.immuni.2009.06.019 · Cited by 481
Self-citationBiomarkers of gastric cancer: Current topics and future perspective
Matsuoka, T., & Yashiro, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i26.2818 · Cited by 476
Parkes, E. E., Walker, S. M., Taggart, L. E., McCabe, N., Knight, L. A., Wilkinson, R., McCloskey, K. D., Buckley, N. E., Savage, K. I., Salto-Tellez, M., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw199 · Cited by 462
Shi, F., Shi, M., Zeng, Z., Qi, R., Liu, Z., Zhang, J., Yang, Y., Tien, P., & Wang, F. (2011) · International Journal of Cancer · doi:10.1002/ijc.25397 · Cited by 464
Wu, M., Huang, Q., Xie, Y., Wu, X., Ma, H., Zhang, Y., & Xia, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01242-2 · Cited by 456
Metabolic and epigenetic regulation of T-cell exhaustion
Franco, F., Jaccard, A., Romero, P., Yu, Y.-R., & Ho, P.-C. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00280-9 · Cited by 455
Sepsis: Multiple Abnormalities, Heterogeneous Responses, and Evolving Understanding
Iskander, K. N., Osuchowski, M. F., Stearns-Kurosawa, D. J., Kurosawa, S., Stepien, D., Valentine, C., & Remick, D. G. (2013) · Physiological Reviews · doi:10.1152/physrev.00037.2012 · Cited by 453
Youngblood, B., Oestreich, K. J., Ha, S.-J., Duraiswamy, J., Akondy, R. S., West, E. E., Wei, Z., Lu, P., Austin, J. W., Riley, J. L., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.06.015 · Cited by 419
Self-citationNFATc1 Regulates PD-1 Expression upon T Cell Activation
Oestreich, K. J., Yoon, H., Ahmed, R., & Boss, J. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4832 · Cited by 416
Self-citationHigh antigen levels are the cause of T cell exhaustion during chronic viral infection
Mueller, S. N., & Ahmed, R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809818106 · Cited by 406
Self-citationPredictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
Meng, X., Huang, Z., Teng, F., Xing, L., & Yu, J. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.001 · Cited by 401
Immune tolerance: What is unique about the liver
Tiegs, G., & Lohse, A. W. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.08.008 · Cited by 394
(2016) · Oncotarget · doi:10.18632/oncotarget · Cited by 386
Kudo, T., Hamamoto, Y., Kato, K., Ura, T., Kojima, T., Tsushima, T., Hironaka, S., Hara, H., Satoh, T., Iwasa, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30181-x · Cited by 377
Post-transcriptional control of cytokine production
Anderson, P. (2008) · Nature Immunology · doi:10.1038/ni1584 · Cited by 376
Sharpe, A. H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00784.x · Cited by 357
Self-citationCD8 T cell dysfunction during chronic viral infection
Shin, H., & Wherry, E. J. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.06.004 · Cited by 348
Self-citationT Cell Dysfunction in Cancer Immunity and Immunotherapy
Xia, A., Zhang, Y., Xu, J., Yin, T., & Lu, X.-J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01719 · Cited by 341
Suarez, E. R., Chang, D.-K., Sun, J., Sui, J., Freeman, G. J., Signoretti, S., Zhu, Q., & Marasco, W. A. (2016) · Oncotarget · doi:10.18632/oncotarget.9114 · Cited by 340
Self-citationProgrammed death-1 (PD-1)–deficient mice are extraordinarily sensitive to tuberculosis
Lázár-Molnár, E., Chen, B., Sweeney, K. A., Wang, E. J., Liu, W., Lin, J., Porcelli, S. A., Almo, S. C., Nathenson, S. G., & Jacobs, W. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007394107 · Cited by 338
Liu, Y., Zugazagoitia, J., Ahmed, F. S., Henick, B. S., Gettinger, S. N., Herbst, R. S., Schalper, K. A., & Rimm, D. L. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1040 · Cited by 322
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
Tang, C., Wang, X., Soh, H., Seyedin, S., Cortez, M. A., Krishnan, S., Massarelli, E., Hong, D., Naing, A., Diab, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0069 · Cited by 322
Mokarizadeh, A., Delirezh, N., Morshedi, A., Mosayebi, G., Farshid, A.-A., & Mardani, K. (2012) · Immunology Letters · doi:10.1016/j.imlet.2012.06.001 · Cited by 320
Franceschini, D., Paroli, M., Francavilla, V., Videtta, M., Morrone, S., Labbadia, G., Cerino, A., Mondelli, M. U., & Barnaba, V. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36604 · Cited by 318
The changing immune system in sepsis: Is individualized immuno-modulatory therapy the answer?
Boomer, J. S., Green, J. M., & Hotchkiss, R. S. (2014) · Virulence · doi:10.4161/viru.26516 · Cited by 317
Kurachi, M. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00744-5 · Cited by 314
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
Beldi-Ferchiou, A., Lambert, M., Dogniaux, S., Vély, F., Vivier, E., Olive, D., Dupuy, S., Levasseur, F., Zucman, D., Lebbé, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12150 · Cited by 312
PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
Gato-Cañas, M., Zuazo, M., Arasanz, H., Ibañez-Vea, M., Lorenzo, L., Fernandez-Hinojal, G., Vera, R., Smerdou, C., Martisova, E., Arozarena, I., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.075 · Cited by 312
Zhang, Y., Zhou, Y., Lou, J., Li, J., Bo, L., Zhu, K., Wan, X., Deng, X., & Cai, Z. (2010) · Critical Care · doi:10.1186/cc9354 · Cited by 308
The Role of PD-1 in Acute and Chronic Infection
Jubel, J. M., Barbati, Z. R., Burger, C., Wirtz, D. C., & Schildberg, F. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00487 · Cited by 307
Nirschl, C. J., & Drake, C. G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1972 · Cited by 306
Brahmamdam, P., Inoue, S., Unsinger, J., Chang, K. C., McDunn, J. E., & Hotchkiss, R. S. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0110037 · Cited by 305
Chang, K., Svabek, C., Vazquez-Guillamet, C., Sato, B., Rasche, D., Wilson, S., Robbins, P., Ulbrandt, N., Suzich, J., Green, J., et al. (2014) · Critical Care · doi:10.1186/cc13176 · Cited by 304
The intracellular signalosome of PD-L1 in cancer cells
Escors, D., Gato-Cañas, M., Zuazo, M., Arasanz, H., García-Granda, M. J., Vera, R., & Kochan, G. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0022-9 · Cited by 292
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Xu-Monette, Z. Y., Zhang, M., Li, J., & Young, K. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01597 · Cited by 288
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Wang, X., Guo, G., Guan, H., Yu, Y., Lu, J., & Yu, J. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1085-3 · Cited by 286
T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion
Utzschneider, D. T., Legat, A., Fuertes Marraco, S. A., Carrié, L., Luescher, I., Speiser, D. E., & Zehn, D. (2013) · Nature Immunology · doi:10.1038/ni.2606 · Cited by 283
Chang, K. C., Burnham, C.-A., Compton, S. M., Rasche, D. P., Mazuski, R., SMcDonough, J., Unsinger, J., Korman, A. J., Green, J. M., & Hotchkiss, R. S. (2013) · Critical Care · doi:10.1186/cc12711 · Cited by 281
The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance
Schönrich, G., & Raftery, M. J. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00207 · Cited by 275
Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
Grosso, J. F., Goldberg, M. V., Getnet, D., Bruno, T. C., Yen, H.-R., Pyle, K. J., Hipkiss, E., Vignali, D. A. A., Pardoll, D. M., & Drake, C. G. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804211 · Cited by 272
Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity
Gianchecchi, E., Delfino, D. V., & Fierabracci, A. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.05.003 · Cited by 270
PD1 signal transduction pathways in T cells
Arasanz, H., Gato-Cañas, M., Zuazo, M., Ibañez-Vea, M., Breckpot, K., Kochan, G., & Escors, D. (2017) · Oncotarget · doi:10.18632/oncotarget.17232 · Cited by 270
He, Y., Yu, H., Rozeboom, L., Rivard, C. J., Ellison, K., Dziadziuszko, R., Suda, K., Ren, S., Wu, C., Hou, L., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.019 · Cited by 268
Mumprecht, S., Schürch, C., Schwaller, J., Solenthaler, M., & Ochsenbein, A. F. (2009) · Blood · doi:10.1182/blood-2008-09-179697 · Cited by 267
Chinnadurai, R., Copland, I. B., Patel, S. R., & Galipeau, J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301828 · Cited by 266
“It is well known that B7H1 and B7DC inhibit the proliferation of PD1 T cells (43), and IFN-g– licensed mouse MSCs have been shown previously to inhibit T cell proliferation through B7H1 (44, 45).”
BackgroundPD-1/PD-L and autoimmunity: A growing relationship
Zamani, M. R., Aslani, S., Salmaninejad, A., Javan, M. R., & Rezaei, N. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2016.09.009 · Cited by 266
PD‐L1 co‐stimulation contributes to ligand‐induced T cell receptor down‐modulation on CD8 + T cells
Karwacz, K., Bricogne, C., MacDonald, D., Arce, F., Bennett, C. L., Collins, M., & Escors, D. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100165 · Cited by 265
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors
Bajaj, G., Wang, X., Agrawal, S., Gupta, M., Roy, A., & Feng, Y. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12143 · Cited by 264
Engineering nanoparticles to locally activate T cells in the tumor microenvironment
Wang, D., Wang, T., Yu, H., Feng, B., Zhou, L., Zhou, F., Hou, B., Zhang, H., Luo, M., & Li, Y. (2019) · Science Immunology · doi:10.1126/sciimmunol.aau6584 · Cited by 261
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283
Zhang, Y., Li, J., Lou, J., Zhou, Y., Bo, L., Zhu, J., Zhu, K., Wan, X., Cai, Z., & Deng, X. (2011) · Critical Care · doi:10.1186/cc10059 · Cited by 259
Jurado, J. O., Alvarez, I. B., Pasquinelli, V., Martínez, G. J., Quiroga, M. F., Abbate, E., Musella, R. M., Chuluyan, H. E., & García, V. E. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.116 · Cited by 258
PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis
Zinselmeyer, B. H., Heydari, S., Sacristán, C., Nayak, D., Cammer, M., Herz, J., Cheng, X., Davis, S. J., Dustin, M. L., & McGavern, D. B. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121416 · Cited by 258
Ilie, M., Hofman, V., Dietel, M., Soria, J.-C., & Hofman, P. (2016) · Virchows Archiv · doi:10.1007/s00428-016-1910-4 · Cited by 257
Bu, D.-X., Tarrio, M., Maganto-Garcia, E., Stavrakis, G., Tajima, G., Lederer, J., Jarolim, P., Freeman, G. J., Sharpe, A. H., & Lichtman, A. H. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.224709 · Cited by 257
Self-citationHow to turn up the heat on the cold immune microenvironment of metastatic prostate cancer
Stultz, J., & Fong, L. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00340-5 · Cited by 242
Cancer Vaccines, Adjuvants, and Delivery Systems
Paston, S. J., Brentville, V. A., Symonds, P., & Durrant, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627932 · Cited by 200
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Hasan Ali, O., Berner, F., Bomze, D., Fässler, M., Diem, S., Cozzio, A., Jörger, M., Früh, M., Driessen, C., Lenz, T. L., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.009 · Cited by 187
“%) patients were treated with antiePD-1 (nivolumab or pembrolizumab) or anti-PD-L1 (atezolizumab) treatment alone.”
InfluentialIFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
Thiem, A., Hesbacher, S., Kneitz, H., di Primio, T., Heppt, M. V., Hermanns, H. M., Goebeler, M., Meierjohann, S., Houben, R., & Schrama, D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1403-9 · Cited by 153
Clayton, K. L., Haaland, M. S., Douglas-Vail, M. B., Mujib, S., Chew, G. M., Ndhlovu, L. C., & Ostrowski, M. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302663 · Cited by 134
Metadata
- Authors
- Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J.
- Venue
- Nature Immunology
- Published
- 2007-02-15
- Volume
- 8
- Issue
- 3
- Pages
- 239-245
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W2057499380
- Cited by
- 1,528
- References
- 87
- FWCI
- 24.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.